We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




New Clinical Guidelines Recommend Use of Blood Tests Instead of Brain Scans for Alzheimer’s Diagnosis

By LabMedica International staff writers
Posted on 04 Aug 2025

Alzheimer’s disease is a progressive neurodegenerative condition that remains challenging to diagnose early and accurately, particularly in individuals with cognitive impairment. More...

Despite the availability of tools such as PET imaging and cerebrospinal fluid (CSF) testing, these methods are often costly, less accessible, and not always acceptable to patients.

Many blood-based biomarker (BBM) tests have been introduced to the market, but there is significant variability in their diagnostic accuracy, and patients and clinicians may mistakenly assume these tests are interchangeable. In response to the need for clearer guidance on the responsible use of BBM tests, a new clinical practice guideline (CPG) now aims to help healthcare professionals improve diagnostic precision and reduce misuse of these emerging tools.

The Alzheimer’s Association (Chicago, IL, USA) has released the first in a series of CPGs for the diagnosis, treatment, and care of Alzheimer’s and all other dementia. The guideline focuses on the use of blood-based biomarker tests for patients with objective cognitive impairment being seen in specialized memory care settings. The recommendations are linked to a systematic review using a robust and transparent methodology, and will be updated regularly as evidence evolves.

A panel of 11 clinicians—including neurologists, geriatricians, nurse practitioners, physician assistants, and subject-matter experts—conducted a systematic review of 49 observational studies, evaluating 31 BBM tests that measure biomarkers such as plasma phosphorylated tau (p-tau) and amyloid-beta (Aβ). The tests examined included analytes like p-tau217, %p-tau217, p-tau181, p-tau231, and Aβ42/Aβ40 ratios. Using the GRADE (Grading of Recommendations Assessment, Development and Evaluation) methodology, the panel formulated brand-agnostic, performance-based recommendations.

The guideline outlines two key uses: as a triaging tool when sensitivity is ≥90% and specificity is ≥75%, and as a confirmatory tool when both sensitivity and specificity are ≥90%. It also includes a Good Practice Statement advising that BBM tests be ordered only after comprehensive clinical evaluation and interpreted within the context of each patient’s care. The guideline, published in Alzheimer’s & Dementia: The Journal of the Alzheimer’s Association, underscores that BBM tests, while promising, should not replace clinical judgment or full diagnostic evaluation.

By offering a structured and transparent evidence-based framework, the guideline empowers clinicians to make informed decisions on the appropriate use of BBM tests and ultimately improve outcomes for patients and families affected by Alzheimer’s. The Alzheimer’s Association plans to release additional clinical practice guidelines through its ALZPro initiative, covering topics such as cognitive assessment tools, staging criteria, treatment implementation, and dementia prevention in the coming years.

“Not all BBM tests have been validated to the same standard or tested broadly across patient populations and clinical settings, yet patients and clinicians may assume these tests are interchangeable,” said Rebecca M. Edelmayer, Ph.D., Alzheimer’s Association vice president of scientific engagement and a co-author of the guideline. “This guideline helps clinicians apply these tools responsibly, avoid overuse or inappropriate use, and ensure that patients have access to the latest scientific advancements.”

Related Links:
Alzheimer's Association


Gold Member
Quantitative POC Immunoassay Analyzer
EASY READER+
POC Helicobacter Pylori Test Kit
Hepy Urease Test
New
Hemodynamic System Monitor
OptoMonitor
New
ESR Analyzer
TEST1 2.0
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: The cell-based tests bring artificial intelligence to transplant outcome care (Photo courtesy of iStock)

AI-Enhanced Cell-Based Blood Tests to Improve Predictive Accuracy for Complex Transplant Outcomes

Managing immunosuppressive drugs in transplant patients is a delicate challenge. Insufficient medication can lead to rejection, which may be cell- or antibody-mediated, while excess immunosuppression raises... Read more

Hematology

view channel
Image: The microfluidic device for passive separation of platelet-rich plasma from whole blood (Photo courtesy of University of the Basque Country)

Portable and Disposable Device Obtains Platelet-Rich Plasma Without Complex Equipment

Platelet-rich plasma (PRP) plays a crucial role in regenerative medicine due to its ability to accelerate healing and repair tissue. However, obtaining PRP traditionally requires expensive centrifugation... Read more

Immunology

view channel
Image: PD-1 protein blockade is the standard treatment for advanced melanoma among the different types of immunotherapy (Photo courtesy of 123RF)

Precision Tool Predicts Immunotherapy Treatment Failure in Melanoma Patients

Melanoma, though accounting for only about 4% of skin tumors, is the deadliest form of skin cancer due to its high potential to metastasize. While immunotherapy, especially PD-1 protein blockade, has revolutionized... Read more

Pathology

view channel
Image: A saliva test can help predict future metabolic health concerns including diabetes and obesity (Photo courtesy of 123RF)

Saliva Test to Enable Early Detection of Diabetes and Obesity

Type 2 diabetes affects about 400 million people globally and is typically diagnosed through elevated blood glucose levels. However, conditions like insulin resistance and hyperinsulinemia may begin developing... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.